← All trials
NCT05052437
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2020
- Primary completion
- Oct 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Sep 22, 2021
- Last posted
- Sep 22, 2021
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BiostarLead sponsor
- Central South UniversityOverall official - principal investigator
- BiostarCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.